The event frequency meta-analysis showed that patients with IBD treated with GLP1-RAs had similar advanced therapy initiation (OR: 0.78, 95% CI: 0.41-1.49, I2 = 85%, P = 0.44) events compared to non-GLP1-RA treatment (Figure 4). The gene discussed is GCG; the disease is inflammatory bowel disease.